Lung Cancer, Hepatocellular Carcinoma / Atezolizumab · Observational Study

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

ClinicalTrials.gov · September 11, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a recruiting, multi-country non-interventional observational study designed to assess patient-reported satisfaction (TASQ-SC), quality of life, and safety of subcutaneous atezolizumab in routine clinical practice for lung cancer and hepatocellular carcinoma. No results are reported in this registry record, and the study remains actively enrolling; clinical interpretation is not yet possible.

What was studied

Observational. Lung Cancer, Hepatocellular Carcinoma; age from 18 Years. Intervention: Cohort 1: Early Non-small Cell Lung Cancer (NSCLC); Cohort 2: Metastatic NSCLC; Cohort 3: Extensive stage small cell lung cancer (ES-SCLC); Cohort 4: Hepatocellular Carcinoma (HCC). n = 700. 92 sites across 8 countries.

Key findings

Safety

Primary outcome is patient-reported satisfaction (TASQ-SC), a surrogate measure, not clinical efficacy or safety events.

Who this may help

This study does not yet provide clinical evidence. Clinicians should await publication of results before interpreting findings on patient satisfaction, quality of life, or safety of subcutaneous atezolizumab.

Plain-language summary

This is a recruiting observational registry study with no reported results; it measures patient satisfaction and quality of life with a surrogate endpoint (TASQ-SC), not clinical outcomes, and cannot inform practice decisions until data are published.

Study design

As stated by the source record.

MethodsCohort model. Prospective time perspective. Primary outcome measure: Therapy Administration Satisfaction Questionnaire Subcutaneous (TASQ-SC) Score (assessed at At Cycle 2 and Cycle 3 (each cycle duration/length is 3 weeks))

DesignObservational

PopulationLung Cancer, Hepatocellular Carcinoma; age from 18 Years

Sample size700

InterventionCohort 1: Early Non-small Cell Lung Cancer (NSCLC); Cohort 2: Metastatic NSCLC; Cohort 3: Extensive stage small cell lung cancer (ES-SCLC); Cohort 4: Hepatocellular Carcinoma (HCC)

Setting92 sites across 8 countries

Reported figures

Quoted from the source exactly as published.

Planned enrollment700

Primary outcome measureTherapy Administration Satisfaction Questionnaire Subcutaneous (TASQ-SC) Score at Cycle 2 and Cycle 3

Study phaseObservational (non-interventional)

Clinical bottom line

Caveats

No results are reported in this registry record; study is actively recruiting.
Primary outcome is patient-reported satisfaction (TASQ-SC), a surrogate measure, not clinical efficacy or safety events.
Observational design without control arm limits causal inference.
Specific inclusion/exclusion criteria, follow-up duration, and data analysis plan not described in registry summary.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

limited

Non-interventional observational design; no control arm or randomization.

Directness

limited

Primary endpoint is patient satisfaction questionnaire, not clinical efficacy or hard outcomes.

Consistency

insufficient

No results reported; consistency cannot be assessed against other evidence.

Risk of bias

insufficient

Registry record only; no methods detail on data collection, blinding, or bias mitigation.

Sample adequacy

moderate

Estimated enrollment 700 participants across multiple cohorts and countries is reasonable.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07284121). This is a study registration, not published results. Lead sponsor: Hoffmann-La Roche. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 700 participants (ESTIMATED). Conditions: Lung Cancer, Hepatocellular Carcinoma. Interventions: DRUG: Atezolizumab. Primary outcome measures: Therapy Administration Satisfaction Questionnaire Subcutaneous (TASQ-SC) Score , At Cycle 2 and Cycle 3 (each cycle duration/length is 3 weeks). Brief summary: This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Lung Cancer, Hepatocellular CarcinomaAtezolizumabNCT07284121Hoffmann-La Roche